AACR's Seventh Annual Landon Awards(otential novel anti-cancer therapies. ...),Health

The work of Dr. Arnold Levine has proven to be a cornerstone in our understanding of cancer on the molecular level, said Lewis C. Cantley, Ph.D., professor in the department of systems biology, Harvard Medical School and chair of the Kirk A. Landon-AACR Prize for Basic Cancer Research selection committee. With the discovery of the p53 tumor suppressor came a heightened interest and renewed fervor in building upon this area of basic cancer research. Decades later, researchers are still uncovering new pieces to the p53 puzzle, and Dr. Levines influential thinking and trail-blazing work remain highly relevant to continued progress in molecular cancer research.

An AACR member of long standing, Levine serves on the AACRs Council of Scientific Advisors and is the program chair of AACRs upcoming meeting, Frontiers in Basic Cancer Research. He is a member of the National Academy of Sciences and served as chairman of the Institute of Medicines National Cancer Policy Board from 2000-2002. Levine has received numerous honors and awards, including most recently: the G.H.A. Clowes Memorial Award from the AACR; the Bristol-Myers Squibb Freedom to Discover Award; the Award for Basic Research from the Surgical Society of Oncologists; the Jill Rose Award from the Breast Cancer Research Foundation; the Albany Medical Center Prize in Medicine and Biomedical Research; and the National Cancer Institutes Alfred Knudson Award in Cancer Genetics. He is also a member of scientific advisory boards at several cancer centers. Levine holds a Ph.D. in microbiology from the University of Pennsylvania and a B.A. from Harpur College, State University of New York at Binghamton.

Throughout his distinguished career, Mendelsohn has dedicated his research efforts to understanding how growth factors regulate the proliferation of cancer cells by ac
'/>"/>